Összesen 2 találat.


001-es BibID:BIBFORM103012
035-os BibID:(Scopus)85102939985 (WOS)000631262400001 (cikkazonosító)611597
Első szerző:Hayden Zsófia
Cím:Clinical Characteristics and Outcome of Neuronal Surface Antibody-Mediated Autoimmune Encephalitis Patients in a National Cohort / Hayden Zsófia, Bóné Beáta, Orsi Gergely, Szots Monika, Nagy Ferenc, Csépány Tünde, Mezei Zsolt, Rajda Cecília, Simon Diána, Najbauer József, Illes Zsolt, Berki Timea
Megjegyzések:Background: In our previous single-center study of autoimmune encephalitis (AE) related autoantibody test results we found positivity in 60 patients out of 1,034 with suspected AE from 2012 through 2018 as part of a Hungarian nationwide program. In our current multicenter retrospective study, we analyzed the clinical characteristics and outcome of AE patients with positive neuronal cell surface autoantibody test results. Methods: A standard online questionnaire was used to collect demographic and clinical characteristics, laboratory and imaging data, therapy and prognosis of 30 definitive AE patients in four major clinical centers of the region. Results: In our study, 19 patients were positive for anti-NMDAR (63%), 6 patients (20%) for anti-LGI1, 3 patients for anti-GABABR (10%) and 3 patients for anti-Caspr2 (10%) autoantibodies. Most common prodromal symptoms were fever or flu-like symptoms (10/30, 33%). Main clinical features included psychiatric symptoms (83%), epileptic seizures (73%) and memory loss (50%). 19 patients (63%) presented with signs of central nervous system (CNS) inflammation, which occurred more frequently in elder individuals (p = 0.024), although no significant differences were observed in sex, tumor association, time to diagnosis, prognosis and immunotherapy compared to AE patients without CNS inflammatory markers. Anti-NMDAR encephalitis patients were in more severe condition at the disease onset (p = 0.028), although no significant correlation between mRS score, age, sex and immunotherapy was found. 27% of patients (n = 8) with associated tumors had worse outcome (p = 0.045) than patients without tumor. In most cases, immunotherapy led to clinical improvement of AE patients (80%) who achieved a good outcome (mRS ? 2; median follow-up 33 months). Conclusion: Our study confirms previous publications describing characteristics of AE patients, however, differences were observed in anti-NMDAR encephalitis that showed no association with ovarian teratoma and occurred more frequently among young males. One-third of AE patients lacked signs of inflammation in both CSF and brain MRI, which emphasizes the importance of clinical symptoms and autoantibody testing in diagnostic workflow for early introduction of immunotherapy, which can lead to favorable outcome in AE patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Frontiers in Neurology. - 12 (2021), p. 1-11. -
További szerzők:Bóné Beáta Orsi Gergely Szots Monika Nagy Ferenc (neurológus Kaposvár) Csépány Tünde (1956-) (neurológus, pszichiáter) Mezei Zsolt (1979-) (neurológus) Rajda Cecília Simon Diána Najbauer József Illés Zsolt (neurológus, Pécs) Berki Tímea
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat


001-es BibID:BIBFORM116231
035-os BibID:(cikkazonosító)183 (scopus)85164167253 (wos)001022417900001
Első szerző:Rajda Cecília
Cím:Treatment of relapsing multiple sclerosis in Hungary : consensus recommendation from the Hungarian neuroimmunology society / Rajda Cecilia, Rózsa Csilla, Mike Andrea, Lovas Gábor, Mezei Zsolt, Jakab Gábor, Ács Péter, Rum Gábor, Simó Magdolna, Jobbágy Zita, Bíró Zita, Trauninger Anita, Imre Piroska, Mátyás Klotild, Deme István, Illés Zsolt, Csepany Tunde
Megjegyzések:Multiple sclerosis (MS) may impact quality of life, careers and family plans of the affected individuals. The current treatments with disease modifying therapies aim to prevent people with MS (pwMS) from disability accumulation and progression. Different countries have different reimbursement policies resulting in inequalities in patient care among geographical regions. Access to anti-CD20 therapies for relapsing MS is restricted in Hungary because therapy of individual cases only is reimbursed. In the light of the latest research and national guidelines, 17 Hungarian MS experts agreed on 8 recommendations regarding relapsing pwMS using the Delphi round method. Strong agreement (>80%) was achieved in all except one recommendation after three rounds, which generated a fourth Delphi round. The experts agreed on treatment initiation, switch, follow-up and discontinuation, as well as on special issues such as pregnancy, lactation, elderly population, and vaccination. Well-defined national consensus protocols may facilitate dialogue between policymakers and healthcare professionals and thus contribute to better patient care in the long run.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Multiple sclerosis
Megjelenés:Orphanet Journal of Rare Diseases. - 18 : 1 (2023), p. 1-8. -
További szerzők:Rózsa Csilla Mike Andrea (neurológus, Pécs) Lovas Gábor Mezei Zsolt (1979-) (neurológus) Jakab Gábor Ács Péter Rum Gábor Simó Magdolna Jobbágy Zita Bíró Zita Trauninger Anita (Pécs orvos) Imre Piroska Mátyás Klotild Deme István Illés Zsolt (neurológus, Pécs) Csépány Tünde (1956-) (neurológus, pszichiáter)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Rekordok letöltése1